Neoadjuvant liposomal irinotecan plus 5‑FU/leucovorin and oxaliplatin with adebrelimab and radiotherapy for resectable or borderline resectable pancreatic cancer with high‑risk features

Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study

This Phase 2 trial tests whether adding the immunotherapy adebrelimab to a neoadjuvant chemo regimen (liposomal irinotecan, 5‑FU/leucovorin, oxaliplatin) with radiotherapy helps patients with resectable or borderline resectable pancreatic cancer who have high‑risk features before surgery.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Ningbo Medical Center Lihuili Hospital (other gov)
• Drugs / interventions: adadelimab, chemotherapy, immunotherapy, adabelimab
• Locations: 1 site (Ningbo)
• Trial ID: NCT07542002 on ClinicalTrials.gov

What this trial studies

This is a prospective, single‑center Phase 2 interventional study enrolling adults with histologically or cytologically confirmed resectable or borderline resectable pancreatic ductal cancer who have high‑risk features. Participants receive a neoadjuvant regimen of liposomal irinotecan, 5‑fluorouracil/leucovorin, and oxaliplatin combined with radiotherapy, with some participants also receiving the immunotherapy agent adebrelimab. The trial is designed to examine safety, treatment tolerability, and the effect of the combination on surgical resectability and early oncologic outcomes. Multidisciplinary tumor board review determines eligibility and surgical decision‑making after neoadjuvant therapy.

Who should consider this trial

Good fit: Adults aged 18–75 with histologically or cytologically confirmed pancreatic ductal adenocarcinoma judged resectable or borderline resectable with high‑risk vascular features by a multidisciplinary team, and who are fit for combined chemotherapy, radiotherapy, and immunotherapy, are ideal candidates.

Not a fit: Patients with unresectable or metastatic pancreatic cancer, poor performance status, major comorbidities, or contraindications to the study drugs or radiotherapy are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the combination could increase the rate of successful surgery and reduce early recurrence for patients with resectable or borderline resectable pancreatic cancer who have high‑risk features.

How similar studies have performed: Single‑agent immunotherapy has shown limited benefit in pancreatic cancer historically, while early-phase studies combining chemotherapy, radiation, and immunotherapy remain exploratory with only modest and variable signals of promise.

Eligibility criteria

Inclusion Criteria:

Patients must meet the following criteria to be eligible for enrollment in this study:

1. Age 18 to 75 years, regardless of gender;
2. Histologically or cytologically confirmed pancreatic cancer (arising from the pancreatic ductal epithelium), as assessed by a multidisciplinary team (MDT), with clinical records indicating resectable or borderline resectable pancreatic cancer with high-risk factors. (According to the 2022 edition of the CSCO guidelines, borderline resectable pancreatic cancer is defined as: ① Tumor contact with the portal vein-superior mesenteric vein \> 180°, or contact ≤180° combined with irregular venous contour or venous thrombosis, but with the possibility of complete resection and safe reconstruction; tumor contact with the inferior vena cava; ② (For pancreatic head/uncinate process tumors) Tumor contact with the common hepatic artery, but without involvement of the celiac artery or the origin of the left or right hepatic arteries, with the possibility of complete resection and safe reconstruction; tumor contact with the superior mesenteric artery ≤180°; tumor contact with variant arteries (e.g., accessory right hepatic artery, replaced right hepatic artery, replaced common hepatic artery, etc.). (For pancreatic body/tail tumors) Tumor contact with the superior mesenteric artery ≤180°; tumor contact with the celiac artery ≤180°.) (According to the 2022 edition of the CSCO guidelines, high-risk factors are defined as "very high CA19-9, large primary tumor, massive regional lymph node metastasis, significant weight loss, and severe pain." In this study, high-risk factors are defined as "CA199 \> 200 U/mL, maximum tumor diameter \> 2 cm, N1 or higher.")
3. Presence of at least one measurable lesion as a target lesion (according to RECIST v1.1 criteria);
4. No prior anti-tumor treatment (including radiotherapy, ablation, chemotherapy, targeted therapy, immunotherapy, etc.) or investigational drug therapy;
5. ECOG performance status: 0-1;
6. Life expectancy of ≥ 3 months;
7. Adequate function of major organs, defined as meeting the following criteria (without transfusion of blood products or administration of hematopoietic growth factors within 14 days prior to randomization):

(1) Absolute neutrophil count ≥ 1.5 × 10⁹/L; platelets ≥ 80 × 10⁹/L; hemoglobin ≥ 9 g/dL; serum albumin ≥ 3 g/dL; (2) Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (biliary drainage is permitted for biliary obstruction); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN (for patients with liver metastasis, up to ≤ 5 × ULN is allowed); (3) Serum creatinine ≤ 1.5 × ULN, and creatinine clearance ≥ 60 mL/min; (4) International Normalized Ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (patients on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, with INR within the therapeutic range of the anticoagulant, are eligible for screening); (5) Electrocardiogram: QTcF ≤ 450 ms (male), ≤ 470 ms (female); (6) Echocardiogram: Left ventricular ejection fraction (LVEF) ≥ 50%; 8. Women of childbearing potential must have a negative serum pregnancy test within 3 days prior to randomization and agree to use an appropriate method of contraception during the study and for 6 months after the end of treatment. For men, they should be surgically sterile or agree to use an appropriate method of contraception during the study and for 3 months after the end of treatment; 9. The subject voluntarily agrees to participate in this study and provides written informed consent.

Exclusion Criteria:

Patients with any of the following criteria are ineligible for enrollment in this study:

1. Pancreatic cancer originating from non-ductal epithelium of the pancreas, including pancreatic neuroendocrine tumors, pancreatic acinar cell carcinoma, pancreatoblastoma, and solid-pseudopapillary neoplasms;
2. Patients with known central nervous system metastasis;
3. Severe gastrointestinal dysfunction (e.g., bleeding, obstruction; inflammation greater than Grade 2; diarrhea greater than Grade 1);
4. Presence of third-space effusions (other than ascites) that cannot reach a stable state within 2 weeks prior to randomization (e.g., large pleural effusion that requires intervention after removal of drainage);
5. Clinically symptomatic ascites requiring paracentesis or drainage, or patients who have undergone ascites drainage within the past 3 months (exceptions include those with minimal ascites detectable only on imaging and controllable without clinical symptoms);
6. Known interstitial lung disease, excluding interstitial changes detected only on imaging;
7. Known peripheral neuropathy (CTCAE ≥ Grade 3);
8. Known deficiency or low activity of dihydropyrimidine dehydrogenase;
9. Severe infection within 4 weeks prior to enrollment (CTCAE \> Grade 2), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications; presence of signs and symptoms of infection within 2 weeks prior to randomization that require intravenous antibiotic therapy (excluding prophylactic use of antibiotics);
10. Receipt of any of the following treatments:

    * Use of strong inhibitors/inducers of CYP3A4, CYP2C8, or strong inhibitors of UGT1A1 within 2 weeks prior to enrollment;
    * Radiotherapy within 2 weeks prior to enrollment;
    * Major surgery (e.g., thoracotomy, laparotomy) within 4 weeks prior to enrollment;
    * Other investigational drug therapy within 4 weeks prior to enrollment, unless it was an observational (non-interventional) clinical study or follow-up of an interventional clinical study;
11. Abnormal coagulation function, tendency to bleed, or ongoing thrombolytic or anticoagulant therapy. Low-dose aspirin (≤100 mg/day) and low molecular weight heparin (e.g., enoxaparin 40 mg/day or equivalent doses of other low molecular weight heparins) for prophylactic use are permitted;
12. Uncontrolled cardiac clinical symptoms or diseases, such as: (1) NYHA Class 2 or higher heart failure; (2) unstable angina; (3) myocardial infarction within the past 6 months; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
13. History of malignancies other than pancreatic cancer within 5 years prior to enrollment, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma of the skin;
14. Known hypersensitivity to irinotecan liposome, other liposomal products, oxaliplatin, 5-FU, leucovorin calcium, adadelimab, or any component of the above products;
15. Known acquired immunodeficiency syndrome (AIDS) or HIV-positive status, active syphilis infection;
16. History of definite neurological or psychiatric disorders, including epilepsy or dementia;
17. As judged by the investigator, the subject has other factors that may lead to forced discontinuation of the study, such as non-compliance with the protocol, concomitant treatment required for other severe diseases (including psychiatric diseases), clinically significant laboratory abnormalities, family or social factors that may affect the subject's safety or the collection of trial data, etc.

Where this trial is running

Ningbo

• Ningbo Medical Center Lihuili Hospital — Ningbo, China (RECRUITING)

Study contacts

• Study coordinator: SHENGDONG WU

Conditions: Pancreatic Cancer